NSEReply to Clarification- Financial results1d ago · 20 Jul 2026, 06:29 pm
Reply to Clarification- Financial results
Cohance Lifesciences Limited · COHANCE
✦ AI SummaryResults
Cohance Lifesciences Limited has responded to the National Stock Exchange's clarification request regarding its financial results for the quarter ended 30-Sep-2025. The company has provided clarification on the filing of non-machine readable form of financial results and has submitted revised financial results in XBRL format on 17 July 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk3/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
The Exchange had sought clarification from Cohance Lifesciences Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: The response of the Company is enclosed.
Attachments (1)
📄pdf
Download →
SUVENPHARMSUSHEEL_17072026155345_Cohance_Clarification_to_NSE_17072026.pdf
View document text
17 July 2026
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Symbol: COHANCE
Dear Sir/Madam,
Sub: Clarification to the email received from NSE dated 10 July 2026
This is with reference to your email dated 10 July 2026 seeking clarification for Financial results with respect
to Outcome of Board Meeting-Financial Results submitted to the Exchange dated 12-Nov-2025.
We wish to inform you that we have given the clarification regarding filing of Non-Machine Readable Form
of Financial Results in our earlier communication dated 2 July 2026. Further we have submitted the revised
Financial results XBRL on 17 July 2026.
Please take the above on record and close the matter.
Thanking you.
Yours faithfully,
For Cohance Lifesciences Limited
(formerly, Suven Pharmaceuticals Limited)
Sisir K. Mishra
Company Secretary and Compliance Officer